GSK has paused diversity programs for UK staff, citing Trump’s executive orders on DEI policies in the US. The move has sparked concerns from investors and legal experts, as rival AstraZeneca continues its diversity efforts unaffected.
British pharmaceutical giant GSK has halted its diversity and inclusion initiatives for UK employees, citing compliance with US executive orders issued by President Donald Trump.
Key Points:
- Trump's crackdown on DEI: The administration has sought to ban diversity, equity, and inclusion (DEI) programs in federally funded companies, prompting major US corporations like Goldman Sachs, Amazon, and BlackRock to scale back their efforts.
- GSK’s reasoning: The company states that as the US is its largest market and biggest customer, it must ensure legal compliance across operations.
- Policy review underway: GSK has removed references to diversity from its website and paused mentoring programs for women and social mobility initiatives. However, diversity in clinical trials remains unaffected.
Read more business news here.
Reactions & Industry Impact
- Investor concerns: Campaign group ShareAction criticized GSK’s move, warning it could hurt the company’s talent retention and reputation.
- Legal perspective: UK legal experts argue that a British firm is not bound by a US executive order, though the global business climate may influence corporate decisions.
- Contrast with AstraZeneca: Rival AstraZeneca, which also operates in the US, has not changed its diversity policies.
What’s Next?
GSK insists this is a temporary pause while policies are reviewed, but the decision reflects growing corporate uncertainty over DEI initiatives amid US political shifts.
.png%3Falt%3Dmedia%26token%3D00799432-c808-48ba-bfe1-3afa1c3bb752&w=1920&q=75)
.png%3Falt%3Dmedia%26token%3D34325d86-eca1-43ec-8ea5-1dfb4a7d5ba7&w=1920&q=75)
Comments
Have a thought on this? Share it with other readers.